Prevalence of hepatitis C among injectors in Scotland 1989–2000: declining trends among young injectors halt in the late 1990s

We previously reported a continual decline in anti-HCV prevalence among young injectors from Glasgow and Lothian between 1990 and 1997. The original study was extended to ascertain if the anti-HCV prevalence among injectors from Glasgow, Lothian, Tayside and Grampian had changed since 1997. Residual sera from injectors who had undergone attributable anti-HIV testing were tested anonymously for anti-HCV. In all four regions, no significant changes in prevalence were found among those aged <25 years during the late 1990s (Glasgow 1997–9/00: 43%–41%; Lothian 1997–9: 13%–17%; Tayside 1997–9: 45%–35%; Grampian 1996–9: 28%–29%). Among those aged [ges ]25 years, significant decreases in prevalence were only observed in Glasgow (1997–9/00: 79%–72%, P = 0·03) and Lothian (1997–9: 54%–45%, P = 0·05). The findings highlight that existing harm reduction measures, acknowledged as having helped to reduce the spread of HCV, are not sufficient to bring this epidemic under control and reduce transmission to sporadic levels.

[1]  M. Hickman,et al.  Over a decade of syringe exchange: results from 1997 UK survey. , 2002, Addiction.

[2]  S. Hutchinson,et al.  High risk injecting behaviour among injectors from Glasgow: cross sectional community wide surveys 1990–1999 , 2001, Journal of epidemiology and community health.

[3]  S. Hutchinson,et al.  Prevalence of antibodies to hepatitis C virus, HIV and human T-cell leukaemia/lymphoma viruses in injecting drug users in Tayside, Scotland, 1993–7 , 2001, Epidemiology and Infection.

[4]  S. Hutchinson,et al.  Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. , 2001, Scandinavian journal of infectious diseases.

[5]  J. Parry,et al.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? , 2001, American journal of public health.

[6]  D. D. Des Jarlais,et al.  HIV and HCV infection among injecting drug users. , 2000, The Mount Sinai journal of medicine, New York.

[7]  J. Parry,et al.  Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. , 2000, Communicable disease and public health.

[8]  S. Hutchinson,et al.  Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-94: implications for control and prevention of blood-borne viruses. , 2000, Addiction.

[9]  S. Gore,et al.  Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? , 2000, The Journal of infection.

[10]  J. Kaldor,et al.  The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not , 1999, The Medical journal of Australia.

[11]  D. Goldberg,et al.  Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. , 1998, Communicable disease and public health.

[12]  D. Goldberg,et al.  Monitoring the Spread of HIV and AIDS in Scotland 1983 – 1994 , 1996, Scottish medical journal.

[13]  G. Stimson AIDS and injecting drug use in the United Kingdom, 1987-1993: the policy response and the prevention of the epidemic. , 1995, Social science & medicine.

[14]  L. Elliott,et al.  Building a city wide service for exchanging needles and syringes. , 1993, BMJ.

[15]  R. Brettle HIV and harm reduction for injection drug users. , 1991, AIDS.